Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares traded up 4.3% during trading on Tuesday . The company traded as high as $4.94 and last traded at $4.86, with a volume of 959,757 shares trading hands. The stock had previously closed at $4.66.

Several analysts have issued reports on the stock. Mizuho restated a “neutral” rating and set a $5.00 price target (down from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Wells Fargo & Co. restated an “underperform” rating on shares of Ziopharm Oncology in a research report on Friday, July 15th. Griffin Securities restated a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research report on Friday, July 1st. Raymond James Financial Inc. assumed coverage on shares of Ziopharm Oncology in a research report on Thursday, June 2nd. They set a “market perform” rating for the company. Finally, Zacks Investment Research lowered shares of Ziopharm Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $10.57.

The stock’s market capitalization is $628.94 million. The firm has a 50 day moving average price of $5.81 and a 200-day moving average price of $6.84.

Ziopharm Oncology (NASDAQ:ZIOP) last announced its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by $0.01. The company earned $1.97 million during the quarter, compared to analysts’ expectations of $1.89 million. During the same quarter in the previous year, the business earned ($0.69) EPS. Ziopharm Oncology’s revenue was up 623.9% compared to the same quarter last year. Equities research analysts predict that Ziopharm Oncology Inc. will post ($0.42) EPS for the current year.

Other institutional investors have recently made changes to their positions in the company. Morgan Stanley boosted its position in shares of Ziopharm Oncology by 5.1% in the fourth quarter. Morgan Stanley now owns 1,618,205 shares of the biotechnology company’s stock valued at $13,447,000 after buying an additional 78,583 shares during the period. California Public Employees Retirement System boosted its position in shares of Ziopharm Oncology by 567.2% in the fourth quarter. California Public Employees Retirement System now owns 307,366 shares of the biotechnology company’s stock valued at $2,554,000 after buying an additional 261,300 shares during the period. Swiss National Bank boosted its position in shares of Ziopharm Oncology by 2.2% in the fourth quarter. Swiss National Bank now owns 159,220 shares of the biotechnology company’s stock valued at $1,323,000 after buying an additional 3,500 shares during the period. Finally, California State Teachers Retirement System boosted its position in shares of Ziopharm Oncology by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 212,521 shares of the biotechnology company’s stock valued at $1,766,000 after buying an additional 3,354 shares during the period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.